Alirocumab shows promise as treatment to reduce LDL-cholesterol in Phase III study

A recently published clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *